BridgeBio Pharma Inc. (NASDAQ:BBIO) shares traded 1.50% higher at $32.52 on Wall Street last session.
In accordance with the data, 11 analysts cover BridgeBio Pharma Inc. (NASDAQ:BBIO). The consensus rating among analysts is ‘Buy’. As we calculate the median target price by taking the range between a high of $50.00 and a low of $30.00, we find $44.00. Given the previous closing price of $32.04, this indicates a potential upside of 37.33 percent. BBIO stock price is now 106.26% away from the 50-day moving average and 162.32% away from the 200-day moving average. The market capitalization of the company currently stands at $4.96B.
It has been rated a hold by 1 analysts and a buy by 9. Brokers who have rated the stock have averaged $43.00 as their price target over the next twelve months.
With the price target enhanced from $24 to $33, Jefferies Downgraded its rating from Buy to Hold for BridgeBio Pharma Inc. (NASDAQ: BBIO).
In other news, Kumar Neil, CEO and President sold 51,552 shares of the company’s stock on May 17. The stock was sold for $722,218 at an average price of $14.01. Upon completion of the transaction, the CEO and President now directly owns 4,813,197 shares in the company, valued at $156.53 million. An SEC document containing details of the transaction can be found on the SEC’s website. On May 17, Secretary, Treasurer & CFO STEPHENSON BRIAN C sold 24,424 shares of the business’s stock. A total of $342,168 was realized by selling the stock at an average price of $14.01. This leaves the insider owning 36,408 shares of the company worth $1.18 million. Insiders disposed of 1,493,809 shares of company stock worth roughly $48.58 million over the past 1 year. A total of 4.30% of the company’s stock is owned by insiders.
There have been several recent changes in the stakes of large investors in BBIO stock. A new stake in BridgeBio Pharma Inc. shares was purchased by FRAZIER LIFE SCIENCES MANAGEMENT, L.P. during the first quarter worth $38,102,000. MARSHALL WACE, LLP invested $35,271,000 in shares of BBIO during the first quarter. In the first quarter, AVIDITY PARTNERS MANAGEMENT LP acquired a new stake in BridgeBio Pharma Inc. valued at approximately $32,520,000. EVENTIDE ASSET MANAGEMENT, LLC acquired a new stake in BBIO for approximately $30,607,000. IKARIAN CAPITAL, LLC purchased a new stake in BBIO valued at around $19,339,000 in the second quarter. In total, there are 257 active investors with 98.10% ownership of the company’s stock.
BridgeBio Pharma Inc. (NASDAQ: BBIO) opened at $32.08 on Tuesday. During the past 12 months, BridgeBio Pharma Inc. has had a low of $6.55 and a high of $34.28. The fifty day moving average price for BBIO is $16.15 and a two-hundred day moving average price translates $12.51 for the stock.
The latest earnings results from BridgeBio Pharma Inc. (NASDAQ: BBIO) was released for Mar, 2023. According to the Biotechnology Company, earnings per share came in at -$0.92, missing analysts’ expectations of -$0.83 by -0.09. This compares to -$1.38 EPS in the same period last year. The company reported revenue of $1.83 million for the quarter, compared to $1.69 million a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue rose 7.79 percent. For the current quarter, analysts expect BBIO to generate $3.33M in revenue.
